| Description | Jolkinolide B is a bioactive diterpene isolated from the roots of Euphorbia fischeriana Steud. Jolkinolide B induces apoptosis in cancer cells. Jolkinolide B can be used for studies on preventing and treating osteolysis. |
| In vitro | Jolkinolide B has potent anti-inflammatory, and antitumor activities. Jolkinolide B is able to enhance apoptosis of human leukemic HL-60 and THP-1 cells, at least in part, through downregulation of JAK2/STAT3 and bcl-2, and upregulation of Bax and cytosolic cytochrome c. Jolkinolide B inhibited RANKL-induced osteoclast differentiation from bone marrow macrophages (BMMs) without cytotoxicity. Furthermore, the expression of osteoclastic marker genes, such as tartrate-resistant acid phosphatase (TRAP), cathepsin K (CtsK), and calcitonin receptor (CTR), was significantly inhibited. Jolkinolide Binhibited RANKL-induced activation of NF-κB by suppressing RANKL-mediated IκBα degradation. Moreover, Jolkinolide B inhibited RANKL-induced phosphorylation of mitogen-activated protein kinases (p38, JNK, and ERK)[1]. |
| molecular weight | 330.42 |
| Molecular formula | C20H26O4 |
| CAS | 37905-08-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 3.3 mg/mL (10 mM), Sonication is recommended. |
| References | 1. Ma X, et al. Jolkinolide B inhibits RANKL-induced osteoclastogenesis by suppressing the activation NF-κB and MAPK signaling pathways. Biochem Biophys Res Commun. 2014 Mar 7;445(2):282-8. 2. Wang, J., Zhou, Y., Bai, X. et al. Jolkinolide B from Euphorbia fischeriana Steud induces apoptosis in human leukemic U937 cells through PI3K/Akt and XIAP pathways. Mol Cells 32, 451–457 (2011). |